Effect of Low Dose Denosumab on Bone Mineral Density in Postmenopausal Women with Osteoporosis After a Transition From 60mg Dose: A Prospective Observational Study

Introduction:

Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodelling and an increased risk of fracture. We evaluated the effect of low dose denosumab (30mg every 6 months) on the prevention of bone loss following a switch from standard dose (60mg of …